Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-19
2009-08-11
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07572772
ABSTRACT:
The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
REFERENCES:
patent: 4399216 (1983-08-01), Axel
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 5225538 (1993-07-01), Capon et al.
patent: 5521288 (1996-05-01), Linsley et al.
patent: 5580756 (1996-12-01), Linsley et al.
patent: 5883223 (1999-03-01), Gray
patent: 5885796 (1999-03-01), Linsley et al.
patent: 6352694 (2002-03-01), June et al.
patent: 6444792 (2002-09-01), Gray et al.
patent: 6534055 (2003-03-01), June et al.
patent: 6641809 (2003-11-01), Linsley et al.
patent: 6685941 (2004-02-01), Thompson et al.
patent: 6719972 (2004-04-01), Gribben et al.
patent: 6750334 (2004-06-01), Gray et al.
patent: 6830937 (2004-12-01), Linsley et al.
patent: 2001/0053361 (2001-12-01), Thompson et al.
patent: 2002/0031510 (2002-03-01), Larsen et al.
patent: 2002/0039577 (2002-04-01), Townsend et al.
patent: 2002/0115214 (2002-08-01), June et al.
patent: 2002/0182211 (2002-12-01), Peach et al.
patent: 2003/0007968 (2003-01-01), Larsen et al.
patent: 2003/0022836 (2003-01-01), Larsen et al.
patent: 2003/0083246 (2003-05-01), Cohen et al.
patent: 2003/0219863 (2003-11-01), Peach et al.
patent: 2004/0014171 (2004-01-01), Peach et al.
patent: 2004/0022787 (2004-02-01), Cohen et al.
patent: 1338323 (1996-05-01), None
patent: 0 613 944 (1994-09-01), None
patent: 0 682 039 (1995-11-01), None
patent: WO93/00431 (1993-01-01), None
patent: WO93/19767 (1993-10-01), None
patent: WO94/28912 (1994-12-01), None
patent: WO95/33770 (1995-12-01), None
patent: WO97/28267 (1997-08-01), None
patent: WO2004/058800 (2004-07-01), None
patent: WO2004/058944 (2004-07-01), None
patent: WO2005/016266 (2005-02-01), None
Attwood T., Science 2000; 290:471-473.
Skolnick et al., Trends in Biotech. 2000; 18(1):34-39.
Janeway, C. A., Jr., “Approaching the Asymptote? Evolution and Revolution in Immunology,”Cold Spring Harbor Symposia on Quantitative Biology, 1989, 65:1-13.
Shaw, S. and Y. Shimuzu, “Two molecular pathways of human T cell adhesion: establishment of receptor-ligand relationship,”Current Opinion in Immunology, 1988, 1:92-7.
Hemler, Martin E., “Adhesive protein receptors on hematopoietic cells,”Immunology Today, 1988, 9:109-13.
Kakiuchi, T. et al., “B Cells as Antigen-Presenting Cells: The Requirement for B Cell Activation,”Journal of Immunology, 1983, 131:109-14.
Krieger, Jeffrey I. et al., “Antigen Presentation By Splenic B Cells: Resting B Cells are Ineffective, Whereas Activated B Cells are Effective Accessory Cells for T Cell Responses,”Journal of Immunology, 1985, 135:2937-45.
Mckenzie, Douglas, “Alloantigen Presentation By B Cells: Requirement for IL-1 And IL-6,”Journal of Immunology, 1988, 141:2907-11.
Hawrylowicz, Catherine M. and Emil R. Unanue, “Regulation of Antigen-Presentation-I IFN-γ Induces Antigen-Presenting Properties on B Cells,”Journal of Immunology, 1988, 141:4083-8.
Springer, Timothy A. et al., “The Lymphocyte Function-Associated LFA-1, CD2, and LFA-3 Molecules: Cell Adhesion Receptors of the Immune System,”Ann. Rev. Immunol., 1987, 5:223-52.
Dinarello, Charles A. and James W. Mier, “Current Concepts: Lymphokines,”New England Journal of Medicine, 1987, 317:940-5.
Weiss, Arthur et al., “The Role of the T3/Antigen Receptor Complex in T-Cell Activation,”Ann. Rev. Immunol, 1986, 4:593-619.
Cobbold, Steve et al., “Non-lineage, LFA-1 family, and leucocyte common antigens: new and previously defined clusters,”Leukocyte Typing III, McMichael, ed., Oxford Univ. Press, Oxford UK, 1987, pp. 788-803.
Moingeon, Philippe et al., “CD2-mediated adhesion facilitates T lymphocyte antigen recognition function,”Nature, 1989, 339:312-4.
Magkoba, Malegapuru W. et al., “ICAM-1 a ligand for LFA-1-dependent adhesion of B, T, and myeloid cells,”Nature, 1988, 331:86-8.
Staunton, Donald E. et al., “Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1,”Nature, 1989, 339:61-4.
Norment, Anne M. et al., “Cell-cell adhesion mediated by CD8 and MHC class I molecules,”Nature, 1988, 336:79-81.
Doyle, Carolyn and Jack L. Strominger, “Interaction between CD4 and class II MHC molecules mediates cell adhesion,”Nature, 1987, 330:256-9.
Stoolman, Lloyd M. “Adhesion Molecules Controlling Lymphocyte Migration,”Cell, 1989, 56:907-10.
Bretscher, Peter and Melvin Cohn, “A Theory of Self-Nonself Discrimination,”Science, 1970, 169:1042-9.
Freeman, Gordon J. et al., “B7, A New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells,”Journal of Immunology, 1989, 143:2714-22.
Freedman, Arnold S. et al., “B7, A B Cell-Restricted Antigen that Identifies Preactivated B Cells,”Journal of Immunology, 1987, 139:3260-7.
Clark, Edward A. et al., “Polypeptides on Human B Lymphocytes Associated with Cell Activation,”Human Immunology, 1986, 16:100-13.
Yokochi, Takashi et al., “B Lymphoblast Antigen (BB-1) Expressed on Epstein-Barr Virus-Activated B Cell Blasts, B Lymphoblastoid Cell Lines, and Burkitt's Lymphomas,”Journal of Immunology, 1982, 128:823-7.
Weiss, Arthur “Structure and Function of the T Cell Antigen Receptor,”J. Clin. Invest., 1990, 86:1015-22.
Allen, Paul M. “Antigen processing at the molecular level,”Immunology Today, 1987, 8:270-3.
Schwartz, Ronald H. “A Cell Culture Model for T Lymphocyte Clonal Anergy,”Science, 1990, 248:1349-56.
Weaver, Casey T. and Emil R. Unanue, “The costimulatory function of antigen-presenting cells,”Immunology Today, 1990, 11:49-55.
Aruffo, Alejandro and Brian Seed, “Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system,”Proc. Natl. Acad. Sci. USA, 1987, 84:8573-7.
Damle, Nitin K. et al., “Alloantigen-Specific Cytotoxic and Suppressor T Lymphocytes are Derived from Phenotypically Distinct Precursors,”Journal of Immunology, 1983, 131:2296-300.
June, Carl H. et al., “T-Cell Proliferation Involving the CD28 Pathway is Associated with Cyclosporine-Resistant Interleukin 2 Gene Expression,”Molecular and Cellular Biology, 1987, 7:4472-81.
Thompson, Craig B. et al., “CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines,”Proc. Natl. Acad. Sci. USA, 1989, 86:1333-7.
Lindsten, Tullia et al., “Regulation of Lymphokine Messenger RNA Stability by a Surface-Mediated T Cell Activation Pathway,”Science, 1989, 244:339-43.
Damle, Nitin K. et al., “Monoclonal antibody analysis of human T lymphocyte subpopulations exhibiting autologous mixed lymphocyte reaction,”Proc. Natl. Acad. Sci. USA, 1981, 78:5096-8.
Lesslauer, Werner et al., “T90/44 (9.3 antigen). A cell surface molecule with a function in human T cell activation,”Eur. J. Immunol., 1986, 16:1289-96.
Linsley, Peter S. et al., “T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1,”Proc. Natl. Acad. Sci. USA, 1990, 87:5031-5.
Linsley, Peter S. et al., “Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation,”J. Exp. Med., 1991, 173:721-30.
Kohno, Keizo et al., “CD28 Molecule as a Receptor-like Function for Accessory Signals in Cell-Mediated Augmentation of IL-2 Production,”Cellular Immunology, 1990, 131:
Brady William
Damle Nitin K.
Ledbetter Jeffrey A.
Linsley Peter S.
Wallace Philip M.
Bristol--Myers Squibb Company
Ouspenski Ilia
Parlet Nickki L.
LandOfFree
Soluble CTLA4 mutant molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Soluble CTLA4 mutant molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble CTLA4 mutant molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4088423